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Prescription drug monitoring programGovernor John Kitzhaber appointed a Prescription Drug Taskforce to address Oregon's opioid epidemic. This
case study reviews the Taskforce's participation in the National Governors Association State Policy Academy
on Reducing Prescription Drug Abuse. To address the challenge of the misuse and abuse of prescription
opioids, the Taskforce developed a strategy for practice change, community education and enhanced access
to safe opioid disposal using stakeholder meetings, consensus development, and ﬁve action steps: (1) fewer
pills in circulation, (2) educate prescribers and the public on the risks of opioid use, (3) foster safe disposal
of unused medication, (4) provide treatment for opioid dependence, and (5) continued leadership from
the Governor, health plans and health professionals. Although the story is ongoing, there are lessons for
leadership in other states and for public health and medical practitioners throughout the country.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction and context
A federal report on nonmedical prescription drug use asserted that
Oregon led the nation in nonmedical use of opioid analgesics. State-level
data from the 2010 and 2011 National Survey on Drug Use and Health
estimated that 6.4% of the Oregon population 12 years or older used
prescription pain relievers in the past year for non-medical reasons
(Substance Abuse and Mental Health Services Administration, 2012).
When theanalysiswas restricted towomenandmenaged18 to25 years,
the rate was even more alarming—15.0% (Substance Abuse and Mental
Health Services Administration, 2012). Clearly, the state had a problem.
Governor Kitzhaber, a practicing emergency physician prior to his
entry into public ofﬁce, recognized the need for action; he asked the
directorof theAlcohol andDrugPolicyCommission (a28member board
that plans, evaluates and coordinates the funding anddelivery of alcohol
and drug prevention and treatment services) to apply to participate in
the 2012/2013 National Governors Association (NGA) State Policy
Academy on Reducing Prescription Drug Abuse (a seven state learning
community addressing prescription drug misuse). This case study
describes the development of Oregon's strategy to better control
prescription opioids and reduce overdoses. A review of the epidemiol-Inc. This is an open access article uogy of opioid use in Oregon provides context for the case study and a
description of the Alcohol and Drug Policy Commission outlines the
vehicle used to convene and coordinate the policy initiative.1.1. Opioid use in Oregon
In addition to leading the nation in the estimated rate
of nonmedical use of prescription opioids during the past year (6.4%
versus the national mean of 4.6%) (Substance Abuse and Mental
Health Services Administration, 2012), opioid overdose fatalities in
Oregon increased ﬁve-fold between 2000 (1 overdose death per
100,000 deaths) and 2006 (5 per 100,000 deaths) and stabilized
between 4 and 5 deaths (per 100,000) in 2006 to 2011 (Millet, 2012).
Overdose deaths related to heroin also increased between 2000
(0.8 overdoses per 100,000 deaths) and 2011 (3.1 overdoses per
100,000 deaths) (Millet, 2012).
Oregon's Prescription Drug Monitoring Program became opera-
tional in 2011 and provides insight into access to prescription opioids.
During a 6 month period (October 2011 through March 2012)
pharmacies ﬁlled 1,872,534 prescriptions for an opioid analgesic
(i.e., hydrocodone, oxycodone, morphine, methadone, fentanyl,
or hydromorphone) to 611,985 unique individuals (rate = 485 ﬁlled
prescriptions per 1000 residents; http://www.orpdmp.com/
orpdmpﬁles/PDF_Files/Reports/PDMP-AC_AnnualReport_2012.pdf).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Prescription Drug Taskforce and Delegation to NGA Policy Academy.
Member Title Description
Rob Bovetta Former District Attorney for Lincoln County, Oregon Prosecutor and state and national drug policy expert
Tom Burns Director of Pharmacy Programs, Oregon Health Authority Responsible for policy issues affecting the purchase of prescription
drugs for publicly funded services.
Judy Cushinga Chief Executive Ofﬁcer, Lines for Life Community leader and prevention expert
Mary Ellen Glynna Former Director, Alcohol and Drug Policy Commission Prepared NGA application
Sean Kolmer Governor's Ofﬁce, Chair of the Delegation Governor Kitzhaber's Health Policy Advisor
Jeff Kruse Oregon State Senator General Assembly leader on healthcare policies and the
Prescription Drug Monitoring Program
Dennis McCartya Professor, Oregon Health & Science University Researcher with expertise in alcohol and drug treatment and prevention
Lisa Millet Section Manager, Oregon Injury and Violence Prevention Program,
Center for Prevention and Health Promotion, Oregon Health Authority
Implemented and manages the Oregon Prescription Drug Monitoring Program
Jim Shames Public Health Ofﬁcer, Jackson County and Josephine County Physician and community leader addressing prescription opioid
overdoses in Southern Oregon
a Member of the Alcohol and Drug Policy Commission.
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have contributed to the rates of individuals prescribed opioids and the
number of opioid prescriptions issued. The Oregon Intractable Pain
Act (passed in 1995; amended in 2003 and 2007) allows physicians to
prescribe controlled substances for treatment of chronic pain without
sanction from the Oregon Medical Board (http://www.oregon.gov/
omb/board/philosophy/Pages/Pain-Management.aspx). The Act pro-
motes adequate treatment of pain. Oregon Administrative Rules
require that chronic pain be assessed and managed and physicians
must inform patients about the risks of opioid therapy; patients must
sign that they have been informed and understand the therapeutic
risks (http://www.oregon.gov/omb/OMBForms1/material-risk-
notice.pdf). The Oregon Pain Commission (http://www.oregon.gov/
oha/OHPR/pages/pmc/index.aspx) advocates for appropriate patient
access to pain management and promoted the 2007 amendments
expanding access to pain medication (http://www.oregon.gov/omb/
OMBForms1/material-risk-notice.pdf). Because of the history of
advocacy for the use of opioid analgesics, Oregon needed to bring
diverse stakeholders to the table (e.g., Oregon Pain Commission,
Oregon Medical Association, Medicaid health plans, commercial
health plans, emergency physicians), document the problem with
reports on overdose fatalities and data on prescription opioids from
the Oregon Prescription Drug Monitoring Program, and seek relative
consensus on how to reduce opioid overdoses and the burden of
opioid abuse.
2. Alcohol and Drug Policy Commission and the
NGA Policy Academy
Oregon legislation in 2009 created the Alcohol and Drug Policy
Commission to coordinate alcohol and drug prevention and treatment
activities across state agencies and to promote integrated data on the
nature and impact of alcohol and drug problems in Oregon (http://
www.doj.state.or.us/adpc/Pages/index.aspx). Commissioners repre-
sent state agencies (e.g., corrections, education, health, human
services, the liquor control board, and the youth authority) and
interest groups directly and indirectly affected by alcohol and drugs
(e.g., healthcare, law enforcement, treatment, prevention and recov-
ery, and research). The Attorney General at the time, John Kroger,
advocated for creation of the Commission and served as the Chair
of the Commission. As a person in recovery and former Federal
prosecutor, Attorney General Kroger understood the personal, public
safety, and public health impacts of alcohol and drug use disorders.
Mr. Kroger's enthusiasm and authority encouraged the leadership
of key state agencies to participate actively in Commission meetings
and initiatives.
The Director of the Commission reports to the Governor's Ofﬁce
and seeks support from participating state agencies for coordinatedprevention and treatment initiatives. In this capacity, the Director,
with support from members of the Commission, prepared and
submitted an application to participate in the NGA State Policy
Academy on Reducing Prescription Drug Abuse. A nine member
Prescription Drug Taskforce formed the Oregon delegation to the
policy academy and blended stakeholders with eclectic perspectives
on public policy (a State Senator, Director of the Alcohol and
Drug Policy Commission, Director of Pharmacy Programs, Governor's
health advisor), public health (county health ofﬁcer, manager of
the prescription monitoring program, public health investigator,
prevention provider), and public safety (county district attorney)
(see Table 1). Taskforce members participated in meetings sponsored
by the NGA and with support from NGA held public forums for
stakeholders in Oregon.
2.1. NGA Policy Academy
The NGA sponsored the Policy Academy to facilitate state
initiatives to reduce prescription drug abuse (http://www.nga.org/
cms/Rx). “Abuse” and “misuse” of prescription opioids were not
explicitly deﬁned; in context, the terms included nonmedical use, the
operation of pill mills, doctor shopping, illicit sales, and other
inappropriate uses of opioids. The Academy received support from
the Robert Wood Johnson Foundation, the Association of State and
Territorial Health Ofﬁcials, and pharmaceutical and healthcare
organizations. The governors of Alabama (Governor Robert Bentley)
and Colorado (Governor John Hickenlooper) hosted the Academy and
a competitive application process selected ﬁve additional states:
Arkansas, Kentucky, New Mexico, Oregon and Virginia. Prior to the
initial 2 day meeting in Montgomery, Alabama (October 22 and 23,
2012), states described their prescription drug monitoring program,
outlined prior regulatory and purchasing strategies to affect prescrip-
tion practices, reviewed support for law enforcement, listed current
partnerships addressing prescription drug abuse and public education
efforts, and noted legislative proposals.
Presentations at the Academy described (a) prescription drug
monitoring programs, (b) strategies supported by pharmaceutical
corporations and retailers to dispose of unused medications and to
reduce illicit sales, and (c) the Ofﬁce of National Drug Control Policy's
Prescription Drug Strategy. The NGA spokesperson acknowledged
that prescription drug misuse included many types of medication but
the Policy Academywould focus on opioidmedications. In subsequent
breakout sessions, states outlined needs and drafted strategies to
address the misuse and abuse of prescription opioids.
The Oregon delegation discussed the nature of Oregon's prescription
drug problems and focused on opioid analgesics. The state senator
explained the need for ongoing access to opioid analgesics by reviewing
his support for the Oregon Intractable Pain Act and his role on the
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opioid overdoses and Oregon's Prescription Drug Monitoring Program.
The Oregon Health Authority valued the Oregon Prescription Drug
Monitoring Programas a tool to informclinical practice and to assess the
effectiveness of public policy interventionsand identify communities for
public and practitioner education. To protect conﬁdentiality, however,
the program's enabling legislation limited access to prescribers
(delegated authority was not allowed), prohibited public safety from
access without a court-order, and constrained the ability of the Oregon
Department of Public Health to link records for data analysis. The
Oregon delegation recognized the need to amend the Oregon
Prescription Drug Monitoring Program's enabling legislation to permit
physicians to delegate staff to access patient data, enhance the use of
data for public health analysis, andpermit the StateMedical Examiner to
access the database in cases of fatal overdose.
The Oregon delegation came to a rapid consensus that public
education and changes in prescriber practices were key elements to
reducing prescription opioid misuse and abuse; arrests and prosecu-
tionswould not solve Oregon's problem. Oregon'smedical practitioners
were wary of restrictive legislative mandates because legislation in
Washington State required prescribers to access the Washington
Prescription Drug Monitoring Program and state policies inhibited
prescriptions for high doses of opioids. Oregon preferred changes in
prescribing practices based on consensual practice standards. To reach
consensus, the PrescriptionDrug Taskforce planned to invite theOregon
Pain Commission, Oregon Medical Board, Oregon Pharmacy Board,
Oregon Medical Association, and health plans to participate in the
conversation and development of the Prescription Drug Strategy.
Transformation of the Oregon Health Plan (Medicaid) created
opportunities for Coordinated Care Organizations (Oregon's version of
Accountable Care Organizations) to systematically address care for
chronic non-cancer pain and to develop public health interventions to
reduce the levels of opioid use in the health plan's population. Oregon's
16 Coordinated Care Organizations (CCOs) integrate physical and
behavioral health care in a single point of accountability (a patient
centered primary care home) to increase access to care, control
healthcare costs and improve health outcomes (McConnell et al.,
2014; Stecker, 2013). The locally governed, regional coalitions of health
care providers and community stakeholders assume ﬁnancial risk using
global budgets and shared savings. The CCOs provided a platform for
partnerships with community prevention programs and treatment
centers for evidence-based prevention and treatment interventions.
The Oregon delegation had prior experience promoting drug take
back initiatives for safe disposal. Despite federal regulations that make
the process burdensome and increase expense, the delegation
supported expansion of drug take backs and development of strong
partnerships with local police departments.
The Oregon delegation outlined plans for engaging stakeholders,
meeting with key groups, and scheduled an initial stakeholder
meeting for early December, 2012 and a larger daylong meeting for
February, 2013. The strategy was developed and approved in time for
the second and ﬁnal Policy Academymeeting scheduled for Denver on
May 6 and 7, 2013.
The NGA Policy Academy efforts continue. The NGA Winter
Meeting in February, 2014 included a discussion of prescription
drug policy and state efforts to reduce the misuse and abuse of
prescription and nonprescription opioids (http://www.nga.org/cms/
home/news-room/news-releases/2014–news-releases/col2-content/
prescription-drug-abuse-focus-of.html). Governors Bentley and Hick-
enlooper reported on lessons learned from the 2012/2013 Policy
Academy. Vermont Governor, Peter Shumlin, and Nevada Governor,
Brian Sandoval, led the 2014/2015 Prescription Drug Abuse Policy
Academy. To expand the learning community and to involve public
health, moreover, NGA and the Association of State and Territorial
Health Ofﬁcers partnered to host webinars and support state initiatives
to reduce prescription opioid misuse.2.2. Stakeholder meetings in Oregon
The Prescription Drug Taskforce hosted two meetings to engage
stakeholders and seek support for a prescription drug strategy. The ﬁrst
(December 5, 2012) included 35 to 40 opinion leaders representing
addiction treatment providers, clinical practitioners, chiefs of police,
communitypreventionprograms,OregonDepartmentof Justice, district
attorneys, emergency departments, the Pain Commission, pain patients,
pharmacists, primary care providers, coordinated care organizations,
Oregon Health Authority, state representatives and senators, state
medical examiner, and the Oregon Medical Board. Taskforce members
described the NGA Policy Academy and the Taskforce's draft strategy.
Breakout sessions allowed stakeholders to discuss emerging recom-
mendations and to suggest ways to enhance their potential effective-
ness. Legislators were briefed on the proposed modiﬁcations to the
Oregon Prescription Drug Monitoring Program.
Governor John Kitzhaber opened the second, larger meeting
(February 7, 2013) with 125 participants. The Governor urged
participants to lead initiatives to reduce prescription drug abuse in
Oregon and asked them to support changes in clinical practice, enhance
take back programs, support public and prescriber education,
and implement evidence-based treatment for opioid dependence
(i.e., opioid agonist and antagonist medications). The forum reviewed
best practices for prescribing opioid analgesics, examined drug disposal
options and inexpensive strategies local police could afford. Data from
the Oregon Prescription Drug Monitoring Program were discussed and
information presented on fatal opioid overdoses. Breakout sessions
examined strategies for changing practice patterns, implementation of
evidence-based treatment for opioid dependence, enhanced public
education, and amending the enabling legislation for the Oregon
Prescription Drug Monitoring Program. There was little disagreement
with the proposed strategies. Oregon has an opioid problem.
3. Opioid strategy and action steps
ThePrescriptionDrugTaskforcedrafteda sevenpageacademicmemo
ﬁlled with data on the need for change and strategies for promoting
change. Working with the Governor's Ofﬁce, the memo was simpliﬁed
and condensed to three pages with ﬁve concise action statements:
• Oregon needs fewer opioid pills in circulation.
• Oregon needs public education on the risks and limits of opioids.
• Oregon needs ways to safely dispose of unwanted prescription opioids.
• Oregon needs to provide treatment for people addicted to
prescription opioids.
• Oregon needs continued leadership from Governor Kitzhaber,
health plans and Coordinated Care Organizations.
With these statements as goals, the Taskforce advocated for
amending the enabling legislation for Oregon's Prescription Drug
Monitoring Program to facilitate checking the database as a routine
practice prior to prescribing opioids. The Taskforce also took
advantage of prescriber education opportunities and partnered with
health plans and health systems to support strategies to reduce
demand for opioid analgesics.
3.1. Amended legislation
The lack of delegated access inhibited prescribers from checking
the Oregon Prescription Drug Monitoring database routinely prior to
writing opioid prescriptions (Deyo et al., 2013). Taskforce members
worked with legislative leadership to amend the legislation and
permit delegated access. To enhance the value for public health,
Senate Bill 470 authorized the Oregon Prescription Drug Monitoring
Program to collect data on patient gender, days of medication, and
reﬁll frequency and permitted public health authorities to use de-
identiﬁed data to inform policy (the initial enabling legislation
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To better understand opioid overdose deaths, the medical
examiner was given authority to access the database. Prescribers in
adjacent states (California, Idaho, and Washington) were allowed
to apply for authorization to access the Oregon Prescription
Drug Monitoring Program. The amendments also allowed prescribers
to review prescriptions dispensed under their Drug Enforcement
Agency number to assure that the number was not being
used fraudulently, and to use these data to monitor their own
prescribing practices. These changes enhanced the monitoring
program, facilitated prescriber access, and contributed to the effort
to modify practice patterns.3.2. Educated prescribers
Practitioner education can enhance changes in clinical practice.
Taskforce members hosted two trainings and partnered with
stakeholders to promote the events. A taskforce member afﬁliated
with the state's medical school facilitated linkages with training
resources speciﬁcally addressing safer opioid prescribing. Neither the
Taskforce nor the Alcohol and Drug Policy Commission had a budget
to support prescriber education. Instead, they took advantage of no-
cost trainings sponsored by the Substance Abuse and Mental Health
Services Administration and a training mandate from the Food and
Drug Administration.
Case Western Reserve University School of Medicine and JBS
International (with support from the Substance Abuse and Mental
Health Services Administration) delivered 6.5 hours of continuing
medical education for prescribers titled “Prescribing Opioids for
Chronic Pain: Balancing Safety and Efﬁcacy.” The training, held August
23, 2013 in Portland, included 5 co-sponsors in addition to the
Taskforce: the Oregon Medical Association, the Board of Pharmacy,
the Oregon Academy of Family Physicians, the Oregon Chapter of the
American Society of Addiction Medicine, and the Oregon Society of
Interventional Pain Management. A presentation on the epidemiology
of opioid abuse included data from the Oregon Prescription Drug
Monitoring Program. The training concluded with discussion of
prescriber practices, practice guidelines on opioid prescriptions for
prescribers working within one of Portland's largest healthcare
systems, and a review of regulatory standards in Oregon. More than
150 prescribers participated. Participants reported being pleased with
the prescribing guidelines because the guidelines helped them resist
requests for increases in medication amounts and strengths that they
did not believe were clinically appropriate.
The Taskforce and the stakeholder groups also partnered with
Boston University School of Medicine to cosponsor “Safe and
Competent Opioid Prescribing Education” (SCOPE of Pain) (Septem-
ber 21, 2013 in Salem). Boston University received an independent
education grant from the Risk Evaluation and Mitigation Strategy
(REMS) Program Companies (the Food and Drug Administration
mandated that manufacturers of extended-release and long-acting
opioid analgesics support prescriber education as part of a Risk
Evaluation and Mitigation Strategy). The FDA Blueprint for Prescriber
Education for Extended-Release and Long-Acting Opioid Analgesics
(Food and Drug Administration, 2013) speciﬁes the content of the
training. The Oregon Prescription Drug Monitoring Program partici-
pated to enroll prescribers. Over 50 prescribers completed the half day
training located in Salem. Fifteen individuals completed an additional
2 hours of training and host regional SCOPE trainings to facilitate
spread of the information. Coordinated Care Organizations (Medicaid
health plans in Oregon) participated in the training and are spreading
the training to their prescribers. The two trainings reached about 200
prescribers. Participation in the Salem trainingwas depressed because
a large CCO in a nearby community sponsored an opioid prescriber
training 2 days prior to the taskforce's training.3.3. Local policies
Oregon's ﬁve point strategy to reduce prescription opioid abuse
encourages policy change to support changes in standards of care. The
Oregon Medical Association posted the prescriber guidelines on its
Web site and promoted statewide standardization of practices. The
primary care clinics and health systems in Clackamas, Multnomah,
andWashington Counties (metropolitan Portland) adopted standard-
ized prescriber guidelines. Statewide, emergency departments share a
common database so they can assess doctor shopping in real time.
While these initiatives may not be a direct product of the Prescription
Drug Taskforce, they reﬂect a zeitgeist that the Taskforce and the
Governor's leadership made more visible and support a consensus
that prescribing practices contributed to the opioid problem in
Oregon and require coordinated attention and change.
In southern Oregon, a taskforce member, Jim Shames, developed
an opioid prescribers workgroup and engaged three Coordinated Care
Organizations to identify physicians whose opioid prescribing
practices exceeded community standards. As the health ofﬁcer
in these counties, Dr. Shames visits outlier practitioners seeking
their participation in the community norms. The opioid prescribers
workgroup uses the Internet to reinforce a sense of community
standards, provide on-line prescriber education, share open access
research papers, and disseminate practice guidelines (www.
opioidprescribersgroup.com). Coordinated Care Organizations in
other regions of the state adopted the southern Oregon change
strategy and sponsored educational interventions for their pre-
scribers. Coordinated Care Organizations also support pain centers
that offer non-opioid therapies and rehabilitation (including alterna-
tive and complementary approaches) and support local prescribers
with challenging patients.
Finally, reﬂecting changing social norms, the Oregon Pain
Commission updated its physician guidance highlighting the risks of
opioids. The adoption and spread of practice guidelines, development
of community standards, and increased attention to the risk of opioid
use reﬂect the use of local policy and promote the Taskforce goal of
“fewer pills in circulation.”
3.4. Remaining challenges
The Taskforce sought to facilitate safe disposal of unused opioid
medication, educate the public, and promote effective treatment for
opioid use disorders. The proposed changes in federal regulations
controlling drug take backs (Department of Justice, Drug Enforcement
Administration, 2012) will permit law enforcement to continue to
conduct take-back events and for the ﬁrst time allow mail-back
programs and collection receptacles in retail pharmacies. Oregon
police chiefs noted the substantial costs of maintaining collection
receptacles and stafﬁng take-backs. Clean air regulations, moreover,
make medication incineration expensive. Oregon eagerly awaits ﬁnal
revised regulations from the Drug Enforcement Agency so that take-
back and disposal opportunities can increase.
Treatment needs are addressed inconsistently and too few patients
have access to medications that reduce craving and enhance recovery.
An analysis of 2011 Medicaid utilization data found that among
8537 Medicaid recipients diagnosed with opioid dependence 530
(6%) had a prescription ﬁlled for an FDA approved medication
for opioid dependence. In the 21st Century, programs that fail to
offer pharmacotherapy and health plans that either refuse to cover
pharmacotherapy or require patients to fail at abstinence-based
therapy not only do their patients andmembers a disservice but stand
in conﬂict with the National Quality Forum's National Consensus
Standards supporting the use of pharmacotherapy for alcohol,
nicotine, and opioid dependence (National Quality Forum, 2007).
The Coordinated Care Organizations can educate theirmembers on
the value of and risks associated with opioid medications, but more
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challenging because resources are limited.
3.5. Sustainability strategy
In December 2013, the Alcohol and Drug Policy Commission
transitioned responsibility for public and practitioner education,
advocacy for take-backs, and promoting access to medication for
treatment of opioid dependence to a community-based prevention
program—Lines for Life. The former U.S. Attorney for Oregon and
current Lines for Life executive director, Dwight Holton, plans ﬁve
Prescription Drug Summits throughout the state and is expanding the
focus to include prescription and non-prescription stimulants as well
as prescription and non-prescription opioids. Members of the
Prescription Drug Taskforce were instrumental in the hand off to
Lines for Life and remain active in the renamed Oregon Coalition for
Responsible Use of Medications (OrCRM). The Coalition membership
includes business leaders, health care providers, law enforcement and
public safety professionals, media experts, addiction prevention and
treatment providers, ministers and chaplains, parents, educators, the
Governor's ofﬁce, members of the Prescription Drug Taskforce, young
adults and individuals in recovery. The ﬁve regional summits will
review local data and initiatives, share promising practices, and
build community consensus and support. Eventually, the Coalition
plans statewide media campaigns on the risks of misusing opioid
and stimulant prescriptions. The campaign is supported through
a small grant from the state and Lines for Life has applied for
a federal Drug-Free Communities award. Partnerships with the
Coordinated Care Organizations and regional prevention services
provide additional resources.
4. Discussion
Under the auspices of the Alcohol and Drug Policy Commission and
the Governor's Ofﬁce, the Prescription Drug Abuse Taskforce engaged
Oregon stakeholders in reviewing data, understanding the problem,
and considering options. Mortality data documented the increased
risk to Oregon residents for overdose related to prescription opioids.
Stakeholders not only agreed that action was required but that
voluntary change in practice standards was preferable to legislated
mandates. Scientists, clinical practitioners, public health experts,
and policy makers partnered to develop ﬁve simple action steps that
encourage state and local efforts to reduce prescription opioid misuse.
Although the change process is still maturing, it appears that there is
widespread acceptance of prescribing guidelines and emergency
departments, primary care clinics, and health care systems applaud
the change.
Oregon recognizes that the problem is not solved. Reducing the
number of pills in circulation requires mechanisms for safe and lawful
disposal of unused medication. Public education is an ongoing need.
Effective treatment for opioid dependence is burdened by myth and
stigma. Nonetheless, Oregon has made progress.
4.1. Limitations
Oregon capitalized on opportunities to participate in the National
Governors Association Policy Academy and to receive high qualitytraining on safer practices for opioid prescribing. In addition, the
Oregon Health Plan's implementation of Coordinated Care Organiza-
tions created regional structures that facilitate prescriber outreach
and changes in prescribing standards. These opportunities may not be
available in other states and Oregon's processes and results may not
generalize. Time,moreover, has been too short to assess the impacts, if
any, from these initiatives. The Oregon Prescription Drug Monitoring
Program continues to track opioid dispensing in the state and issue
periodic reports and assessments. The StateMedical Examiner and the
state Public Health Division and county health departments will
continue to track opioid overdoses and alert the community to the
risks of opioid use and misuse.
Nonetheless, the Oregon process and strategies are likely to be
informative to other states and their policy makers as they confront
the opioid epidemic. Oregon's lessons include (a) the need to facilitate
and simplify use of prescription drug monitoring programs, (b) the
value of prescriber guidelines, (c) use of practice standards rather than
legislation to change prescribing practices, and (d) the importance
of continued leadership from the Governor, health ofﬁcers, medical
associations, health plans, and practitioners.Acknowledgments
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